Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective post remission treatment for leukemia, resulting in lower relapse rates than alternative therapies. However, it is limited by the lack of suitable human leukocyte antigen (HLA) matched donors and high rates of transplant-related morbidity and mortality. Cord blood transplantation (CBT) and haploidentical SCT (haplo-SCT) expand the potential donor pool but are also associated with major complications. Co-infusion of third-party donor stem cellswith a CBT/haplo-SCT, which is called “dual transplantation,” has been reportedto improve the outcome of HSCTby accelerating hematopoietic reconstitution and reducing the incidence of graft-versus-host disease (GVHD). In addition, infusion of HLA-mismatched donor granulocyte colony-stimulating factor–mobilized donor peripheral blood stem cellsafter chemotherapy, the so called “microtransplantation”, has been shown to promote the graft–versus-leukemiaeffect and hasten hematopoietic recovery without amplifying GVHD. Herein, we review recent advances in stem cell therapy for leukemia with a specific focus on dual transplantation and microtransplantation.
Keywords: Allogeneic hematopoietic stem cell transplantation, cord blood, haploidentical, microtransplantation.
Current Stem Cell Research & Therapy
Title:Advances in Stem Cell Therapy for Leukemia
Volume: 11 Issue: 2
Author(s): Hong Tian, Qi Qu, Liming Liu and Depei Wu
Affiliation:
Keywords: Allogeneic hematopoietic stem cell transplantation, cord blood, haploidentical, microtransplantation.
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective post remission treatment for leukemia, resulting in lower relapse rates than alternative therapies. However, it is limited by the lack of suitable human leukocyte antigen (HLA) matched donors and high rates of transplant-related morbidity and mortality. Cord blood transplantation (CBT) and haploidentical SCT (haplo-SCT) expand the potential donor pool but are also associated with major complications. Co-infusion of third-party donor stem cellswith a CBT/haplo-SCT, which is called “dual transplantation,” has been reportedto improve the outcome of HSCTby accelerating hematopoietic reconstitution and reducing the incidence of graft-versus-host disease (GVHD). In addition, infusion of HLA-mismatched donor granulocyte colony-stimulating factor–mobilized donor peripheral blood stem cellsafter chemotherapy, the so called “microtransplantation”, has been shown to promote the graft–versus-leukemiaeffect and hasten hematopoietic recovery without amplifying GVHD. Herein, we review recent advances in stem cell therapy for leukemia with a specific focus on dual transplantation and microtransplantation.
Export Options
About this article
Cite this article as:
Tian Hong, Qu Qi, Liu Liming and Wu Depei, Advances in Stem Cell Therapy for Leukemia, Current Stem Cell Research & Therapy 2016; 11 (2) . https://dx.doi.org/10.2174/1574888X10666151019120217
DOI https://dx.doi.org/10.2174/1574888X10666151019120217 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Male Fertility-Implications of Anticancer Treatment and Strategies to Mitigate Gonadotoxicity
Anti-Cancer Agents in Medicinal Chemistry Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Cytosine Methyltransferases as Tumor Markers
Current Genomics Modified Envelope Glycoproteins to Retarget Retroviral Vectors
Current Gene Therapy Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction
Cardiovascular & Hematological Disorders-Drug Targets Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Strategic siRNA Screening Approaches to Target Cancer at the Cancer Research UK Beatson Institute
Combinatorial Chemistry & High Throughput Screening